Julie Zhang
Reporter, Business
Julie Zhang joined SCMP in 2025 as a business reporter. She was formerly with China Daily Hong Kong Edition for over five years, covering corporate earnings, IPOs, financial regulations, ESG, cryptocurrency and property markets. Her reporting garnered multiple Hong Kong News Awards and Hang Seng University's Business Journalism Award.
Julie Zhang joined SCMP in 2025 as a business reporter. She was formerly with China Daily Hong Kong Edition for over five years, covering corporate earnings, IPOs, financial regulations, ESG, cryptocurrency and property markets. Her reporting garnered multiple Hong Kong News Awards and Hang Seng University's Business Journalism Award.
Areas of Expertise:
Corporate finance, IPOSLanguages Spoken:
Cantonese, English, Mandarin
Gen Z buyers are driving demand for bullion, spurred by geopolitical tensions, inflation and the appeal of owning gold outright.
Chinese regulators have approved a group of brain-technology products this year, as local start-ups push to surpass Musk’s Neuralink.
Family offices and venture investors across Hong Kong and the wider region are reshaping portfolios to capture long-term biotech growth.
De-dollarisation tailwinds, ecosystem buildout and mainland China’s support plus foreign backing give city’s ambitions credible momentum.
Advertisement
Noah Medical expects to file application as early as next year, joining surge of tech listings tapping city’s international fundraising pool.
Launch of commercial BCI implantation, ahead of US, offers hope to millions with brain or spinal injuries as plans are made for the technology’s wider use.
While monthly shipments cool from record highs, banks and logistics giants are racing to secure physical space for the city’s rising bullion trade.
The biliary tract cancer trial is the latest breakthrough for Akeso’s ivonescimab, which has also shown promise in treating some lung cancers.
Chinese biotech firms are already working on more than 100 cancer vaccines. Now, many are seeing their shares surge amid Moderna’s breakthrough.
Out-licensing deals have overtaken IPOs as the primary lifeline for cash-starved Chinese drug makers, analysts say.
By anchoring yuan trades to gold through Hong Kong and new global vaults, Beijing will add convertibility to its currency, report says.
The milestone more than doubles the previous peak recorded in 2018.
Alibaba Cloud among partners chosen to create a platform for Hong Kong’s gold clearing and settlement system next year.
Genscript posted adjusted net profit of US$62.52 million for the six months ended June 30, a 203 per cent year-on-year surge.
Human testing could take up to five years to ramp up, but AI approaches will yield results in time, Karoly Nikolich says.
China is throwing the power of the state behind efforts to overtake Elon Musk in a vital frontier technology: brain-computer interfaces.
Bullion forecasts have softened, LBMA’s survey shows, despite the World Gold Council reporting unprecedented demand in second quarter.
The technology – which allows patients to control digital devices using their thoughts – can be implanted like a stent in just a few minutes.
The foreign investments can help Chinese companies grow and compete on the global stage, according to Citic Securities.
Hong Kong Investment Corporation is stepping up its efforts to position itself amid Beijing’s challenge to US pharmaceutical dominance.
Rising demand from central banks to drive a rebound despite temporary downside pressure from energy and interest rates, Goldman Sachs says.
The number of new accounts opened on the Shanghai Stock Exchange was down 7 per cent month on month.
Strong orders for weight-loss and diabetes treatments drive firm’s growth, despite being caught up in US efforts to curb China’s ambitions.
National Social Security Fund increases onshore stock stakes, targeting tech as state pension returns hit 5.76 per cent.
Pharmaceutical contractor’s GLP-1 programmes and surging stock gains have made it a magnet for global investors.
Chinese mutual funds shifted focus amid market volatility, cutting their share of Hong Kong stocks to 23.3 per cent in the second quarter.
Analysts say that China’s pivot from generics to innovative drugs means the industry is less exposed to US levies.
Push to accelerate novel drug reviews promises earlier access to breakthrough therapies for patients long left waiting.
Axiom Biosciences founder says Hong Kong investors show greater maturity than Nasdaq in handling biotech companies.
